Isavuconazole therapy protects immunosuppressed mice from mucormycosis.
about
Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infectionsIsavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendationsIsavuconazole: A New Option for the Management of Invasive Fungal Infections.A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasisSafety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation studyPharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection modelIn Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales OrderIsavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)Population Pharmacokinetics of Isavuconazole from Phase 1 and Phase 3 (SECURE) Trials in Adults and Target Attainment in Patients with Invasive Infections Due to Aspergillus and Other Filamentous Fungi.Our 2014 approach to mucormycosis.Pathogenesis and host defence against Mucorales: the role of cytokines and interaction with antifungal drugs.Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases.Isavuconazonium: first global approval.The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections.Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis.Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections.Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis.Isavuconazole: a new extended spectrum triazole for invasive mold diseases.Fungal Infections of the Central Nervous System in Children.Prophylaxis with Isavuconazole or Posaconazole Protects Immunosuppressed Mice from Pulmonary Mucormycosis.Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis.Comparison of the EUCAST and CLSI Broth Microdilution Methods for Testing Isavuconazole, Posaconazole, and Amphotericin B against Molecularly Identified Mucorales Species.Molecular characterization and in vitro antifungal susceptibility of 80 clinical isolates of mucormycetes in Delhi, India.Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats.Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.
P2860
Q26744049-272E4AA4-BCC7-4587-B8B5-2BEB7AB04569Q28067726-A4A6C91B-7012-43D7-80C4-D3680D602A2BQ34474946-F6DD0C96-09C1-46C7-A054-D6CFCED00BF5Q35076974-FE77F3E5-713C-4954-BB87-BCA1B3205332Q35168889-A7A505F8-F5B3-482C-8BAA-756CA82B4E83Q35385554-43D5D259-D560-40ED-B9EE-D32368A30A60Q36290764-11109702-3B74-41CC-BDDE-260D82F60976Q37096795-A595EC74-35F5-48E4-81AC-82D36E99052DQ37119937-2490EAEB-78E0-40FC-8182-4101CA297496Q37203893-8A40F327-BF60-43E2-B3F8-F54900CAA954Q38211830-BD8DEF19-6016-4AC9-B723-92571C969D3FQ38245046-238015A3-37B5-42F4-AFA1-A5E90FB185F3Q38285488-65B70058-FCE7-45A3-8C63-20410B4092CDQ38436002-DA5C3E0B-2A4B-40B1-89E7-F7E16846729EQ38534865-B3CA1222-4578-4E4B-90AB-D7FD502BA687Q38829932-0DB33EE3-9B77-4164-875D-622FFBEA282CQ38939506-C2147423-D435-4F7F-94A4-D5FB154223A6Q38987096-42C7B399-9499-465E-9CCE-DF25267A32C0Q39003715-C334CB60-8A0B-4EF7-B074-8BBBE4F4AFCAQ40043020-3A7AD837-2FD4-4AB6-A870-45113F456BAEQ40306219-0612A449-7CB5-4EF9-8761-BE44FAEC149FQ40474311-6214014C-5BFE-426E-A890-C461826CF1C3Q40965373-851339AE-B0CE-4E59-B160-12FD6CC11CC2Q46834709-4F07F443-53C0-4546-9AD2-5CACB7840902Q47151374-0FA5929A-4816-46AB-A69C-A9DA9DE3E05BQ54214603-7739431C-84C1-4415-BEE1-D28A46D81147
P2860
Isavuconazole therapy protects immunosuppressed mice from mucormycosis.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Isavuconazole therapy protects immunosuppressed mice from mucormycosis.
@en
Isavuconazole therapy protects immunosuppressed mice from mucormycosis.
@nl
type
label
Isavuconazole therapy protects immunosuppressed mice from mucormycosis.
@en
Isavuconazole therapy protects immunosuppressed mice from mucormycosis.
@nl
prefLabel
Isavuconazole therapy protects immunosuppressed mice from mucormycosis.
@en
Isavuconazole therapy protects immunosuppressed mice from mucormycosis.
@nl
P2093
P2860
P356
P1476
Isavuconazole therapy protects immunosuppressed mice from mucormycosis.
@en
P2093
Ashraf S Ibrahim
Guanpingsheng Luo
Hongkyu Lee
John E Edwards
Laura Kovanda
Teclegiorgis Gebremariam
P2860
P304
P356
10.1128/AAC.02301-13
P407
P577
2014-02-03T00:00:00Z